Search Results | Cancer Research | American Association for Cancer Research

1-19 of 19

Sort by

Sort Order Select

Journal Articles

TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors

Cancer Res (2021) 81 (19): 5089–5101.

DOI: https://doi.org/10.1158/0008-5472.CAN-20-3761

Published: 01 October 2021

View article

Includes: Supplementary data

Journal Articles

Abstract 2057: BRCA1 D11q isoform expression impacts PARP inhibitor responses in high grade serous ovarian carcinoma patient derived xenografts

Ksenija Nesic, Cassandra J. Vandenberg, Olga Kondrashova, John J. Krais, Neil Johnson, Elizabeth M. Swisher, Matthew J. Wakefield, Clare L. Scott

Cancer Res (2021) 81 (13_Supplement): 2057.

DOI: https://doi.org/10.1158/1538-7445.AM2021-2057

Published: 01 July 2021

View article

Journal Articles

Inhibition of ATM Induces Hypersensitivity to Proton Irradiation by Upregulating Toxic End Joining

Qin Zhou, Michelle E. Howard, Xinyi Tu, Qian Zhu, Janet M. Denbeigh, Nicholas B. Remmes, Michael G. Herman, Chris J. Beltran, Jian Yuan, Patricia T. Greipp, Judy C. Boughey, Liewei Wang, Neil Johnson, Matthew P. Goetz, Jann N. Sarkaria, Zhenkun Lou, Robert W. Mutter

Cancer Res (2021) 81 (12): 3333–3346.

DOI: https://doi.org/10.1158/0008-5472.CAN-20-2960

Published: 15 June 2021

View article

Includes: Supplementary data

Journal Articles

Replication Gaps Underlie BRCA Deficiency and Therapy Response

Nicholas J. Panzarino, John J. Krais, Ke Cong, Min Peng, Michelle Mosqueda, Sumeet U. Nayak, Samuel M. Bond, Jennifer A. Calvo, Mihir B. Doshi, Matt Bere, Jianhong Ou, Bin Deng, Lihua J. Zhu, Neil Johnson, Sharon B. Cantor

Cancer Res (2021) 81 (5): 1388–1397.

DOI: https://doi.org/10.1158/0008-5472.CAN-20-1602

Published: 01 March 2021

View article

Includes: Supplementary data

Journal Articles

BRCA1 Mutations in Cancer: Coordinating Deficiencies in Homologous Recombination with Tumorigenesis

John J. Krais, Neil Johnson

Cancer Res (2020) 80 (21): 4601–4609.

DOI: https://doi.org/10.1158/0008-5472.CAN-20-1830

Published: 03 November 2020

View article

Journal Articles

RNF168-Mediated Ubiquitin Signaling Inhibits the Viability of BRCA1-Null Cancers

John J. Krais, Yifan Wang, Andrea J. Bernhardy, Emma Clausen, Jessica A. Miller, Kathy Q. Cai, Clare L. Scott, Neil Johnson

Cancer Res (2020) 80 (13): 2848–2860.

DOI: https://doi.org/10.1158/0008-5472.CAN-19-3033

Published: 02 July 2020

View article

Includes: Supplementary data

Journal Articles

Abstract 1876: Reduced Pak1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibition

Olga Villamar-Cruz, Tatiana Prudnikova, Neil Johnson, Jonathan Chernoff, Luis E. Arias Romero

Cancer Res (2016) 76 (14_Supplement): 1876.

DOI: https://doi.org/10.1158/1538-7445.AM2016-1876

Published: 15 July 2016

View article

Journal Articles

The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin

Cancer Res (2016) 76 (9): 2778–2790.

DOI: https://doi.org/10.1158/0008-5472.CAN-16-0186

Published: 01 May 2016

View article

Includes: Supplementary data

Journal Articles

Abstract LB-248: Protein arginine methyltransferase 5 (PRMT5) inhibition as a therapeutic strategy in B-cell lymphoma

Olena Barbash, Sarah Gerhart, David Soong, Christine Thompson, Rocio Montes de Oca, Ping Zhang, Charles McHugh, Kristy Kuplast, Christina Majer, Richard Chesworth, Jesse Smith, Robert Copeland, Elayne Penebre, Kenneth Duncan, Neil Johnson, Chris Carpenter, Ryan Kruger

Cancer Res (2015) 75 (15_Supplement): LB-248.

DOI: https://doi.org/10.1158/1538-7445.AM2015-LB-248

Published: 01 August 2015

View article

Journal Articles

Abstract 5379: A potent EZH2 inhibitor exhibits long residence time and anti-tumor activity

Cancer Res (2015) 75 (15_Supplement): 5379.

DOI: https://doi.org/10.1158/1538-7445.AM2015-5379

Published: 01 August 2015

View article

Journal Articles

Abstract 5467: BRCA1 N-terminal-deficient proteins provide PARP inhibitor and platinum resistance

Yifan Wang, Andrea Bernhardy, Emmanuelle Nicolas, Ryan Winters, Kathy Cai, Kelly Duncan, James Duncan, Maria Harrell, Elizabeth Swisher, Neil Johnson

Cancer Res (2015) 75 (15_Supplement): 5467.

DOI: https://doi.org/10.1158/1538-7445.AM2015-5467

Published: 01 August 2015

View article

Journal Articles

Abstract 3513: Inhibition of LSD1 for the treatment of cancer

Cancer Res (2015) 75 (15_Supplement): 3513.

DOI: https://doi.org/10.1158/1538-7445.AM2015-3513

Published: 01 August 2015

View article

Journal Articles

Abstract 1788: The CDK inhibitor dinaciclib sensitizes triple-negative breast cancer cells to PARP inhibition.

Shawn F. Johnson, Neil Johnson, David Chi, Benjamin Primack, Alan D. D'Andrea, Elgene Lim, Geoffrey I. Shapiro

Cancer Res (2013) 73 (8_Supplement): 1788.

DOI: https://doi.org/10.1158/1538-7445.AM2013-1788

Published: 15 April 2013

View article

Journal Articles

Abstract 2979: Combined cdk1 and PARP inhibition results in tumor regression in a KrasG12D p53L/L murine lung adenocarcinoma model

Neil Johnson, Yu-Chen Li, Zandra Walton, Danan Li, Lisa Moreau, Scott J. Rodig, Alan D. D'Andrea, Huw Thomas, David R. Newell, Nicola J. Curtin, Kwok K. Wong, Geoffrey I. Shapiro

Cancer Res (2011) 71 (8_Supplement): 2979.

DOI: https://doi.org/10.1158/1538-7445.AM2011-2979

Published: 15 April 2011

View article

Journal Articles

Abstract 3882: Compromised Cdk1 activity sensitizes BRCA-proficient cancer cells to inhibition of Poly(ADP-ribose) polymerase

Neil Johnson, Yu-Chen Li, Lisa A. Moreau, Huw D. Thomas, David R. Newell, Alan D. D'andrea, Nicola J. Curtin, Geoffrey I. Shapiro

Cancer Res (2010) 70 (8_Supplement): 3882.

DOI: https://doi.org/10.1158/1538-7445.AM10-3882

Published: 15 April 2010

View article

Journal Articles

Abstract #3316: Cdk1 depletion disrupts BRCA1 function and selectively sensitizes cancer cells to DNA damaging agents

Neil Johnson, Dongpo Cai, Richard Kennedy, Shailja Pathania, Jeffrey Parvin, Alan D'Andrea, Geoffrey Shapiro

Cancer Res (2009) 69 (9_Supplement): 3316.

Published: 01 May 2009

View article

Journal Articles

Concomitant CDK1 and CDK2 depletion induces irreparable DNA damage, G2/M arrest and cell death

neil johnson, Dongpo Cai, Geoffrey Shapiro

Cancer Res (2007) 67 (9_Supplement): 4346.

Published: 01 May 2007

View article

Journal Articles

The effect of a novel CDK inhibitor NU2058 on antiestrogen sensitive and resistant breast cancer cell growth and downstream events

Neil Johnson, Nicola J. Curtin

Cancer Res (2005) 65 (9_Supplement): 1046.

Published: 01 May 2005

View article

Journal Articles

The use of novel CDK inhibitors in the treatment of hormone refractory breast cancer

Neil Johnson, Nicola J. Curtin

Cancer Res (2004) 64 (7_Supplement): 190.

Published: 01 April 2004

View article

NARROW

TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors

Abstract 2057: BRCA1 D11q isoform expression impacts PARP inhibitor responses in high grade serous ovarian carcinoma patient derived xenografts

Inhibition of ATM Induces Hypersensitivity to Proton Irradiation by Upregulating Toxic End Joining

Replication Gaps Underlie BRCA Deficiency and Therapy Response

BRCA1 Mutations in Cancer: Coordinating Deficiencies in Homologous Recombination with Tumorigenesis

RNF168-Mediated Ubiquitin Signaling Inhibits the Viability of BRCA1-Null Cancers

Abstract 1876: Reduced Pak1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibition

The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin

Abstract LB-248: Protein arginine methyltransferase 5 (PRMT5) inhibition as a therapeutic strategy in B-cell lymphoma

Abstract 5379: A potent EZH2 inhibitor exhibits long residence time and anti-tumor activity

Abstract 5467: BRCA1 N-terminal-deficient proteins provide PARP inhibitor and platinum resistance

Abstract 3513: Inhibition of LSD1 for the treatment of cancer

Abstract 1788: The CDK inhibitor dinaciclib sensitizes triple-negative breast cancer cells to PARP inhibition.

Abstract 2979: Combined cdk1 and PARP inhibition results in tumor regression in a KrasG12D p53L/L murine lung adenocarcinoma model

Abstract 3882: Compromised Cdk1 activity sensitizes BRCA-proficient cancer cells to inhibition of Poly(ADP-ribose) polymerase

Abstract #3316: Cdk1 depletion disrupts BRCA1 function and selectively sensitizes cancer cells to DNA damaging agents

Concomitant CDK1 and CDK2 depletion induces irreparable DNA damage, G2/M arrest and cell death

The effect of a novel CDK inhibitor NU2058 on antiestrogen sensitive and resistant breast cancer cell growth and downstream events

The use of novel CDK inhibitors in the treatment of hormone refractory breast cancer

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only